Xenon Pharmaceuticals Faces Stock Plunge After Clinical Study Pause

NEW YORK, Oct. 07, 2026 /CourierPR/ -- Wolf Popper LLP, a law firm, is continuing its investigation into potential claims on behalf of investors in Xenon Pharmaceuticals Inc. (NASDAQ: XENE). Xenon is a clinical-stage drug company focused on developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, including focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain.

In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, which was set to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD. However, on September 17, 2026, after the market closed, Xenon announced a voluntary pause in new patient enrollment in its ongoing clinical studies for MDD and bipolar depression following an analysis of neuropsychiatric adverse events in those studies. This announcement sent shockwaves through the stock market, causing Xenon’s share price to plummet.

On September 18, 2026, Xenon’s stock price fell $17.60 per share, marking a 30.7% drop, closing at $39.75. The decline was accompanied by heavy trading volume, signaling significant investor concern. Investors who suffered losses and wish to discuss the investigation are encouraged to contact Wolf Popper LLP.

Wolf Popper LLP has a track record of recovering billions of dollars for defrauded investors and has been appointed to major roles in securities litigation. The firm’s expertise and reputation are well-established in the legal community.